SPARQL
Query
Update
Search
Quick
Advanced
Co-occurrence
RelFinder
About
Sources
Admin
System Info
Repository Management
Search Configuration
Sources
12528875
Source:
http://linkedlifedata.com/resource/pubmed/id/12528875
Search
Subject
(
66
)
Predicate
Object
All
Download in:
JSON
RDF
N3/Turtle
N-Triples
Switch to
Custom View
Named Graph
All
UniProt
NCBIGene
DrugBank
ClinicalTrials
UMLS
PubMed
Mappings
MentionedEntities
Language
All
English
Español
Português
Français
Deutsch
Русский
日本語
Български
Inference
Explicit and implicit
Explicit only
Implicit only
Statements in which the resource exists as a subject.
Predicate
Object
rdf:type
pubmed:Citation
lifeskim:mentions
umls-concept:C0026764
,
umls-concept:C0038952
,
umls-concept:C0039736
,
umls-concept:C0087111
,
umls-concept:C0871261
,
umls-concept:C1521828
,
umls-concept:C1704632
,
umls-concept:C1706817
,
umls-concept:C2911692
pubmed:issue
1
pubmed:dateCreated
2003-1-16
pubmed:abstractText
To assess response rate, duration of response, progression-free survival, and toxicity of thalidomide in patients with relapsed multiple myeloma.
pubmed:grant
http://linkedlifedata.com/resource/pubmed/grant/CA62242
,
http://linkedlifedata.com/resource/pubmed/grant/CA85818
,
http://linkedlifedata.com/resource/pubmed/grant/CA93842
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/12528875-12528872
pubmed:language
eng
pubmed:journal
http://linkedlifedata.com/resource/pubmed/journal/0405543
pubmed:citationSubset
AIM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents
,
http://linkedlifedata.com/resource/pubmed/chemical/Thalidomide
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0025-6196
pubmed:author
pubmed-author:DispenzieriAngelaA
,
pubmed-author:FonsecaRafaelR
,
pubmed-author:GertzMorie AMA
,
pubmed-author:GeyerSusan MSM
,
pubmed-author:GreippPhilip RPR
,
pubmed-author:HaymanSuzanne RSR
,
pubmed-author:IturriaNancy LNL
,
pubmed-author:KumarShajiS
,
pubmed-author:KyleRobert ARA
,
pubmed-author:LacyMartha QMQ
,
pubmed-author:LustJohn AJA
,
pubmed-author:RajkumarS VincentSV
,
pubmed-author:WitzigThomas ETE
pubmed:issnType
Print
pubmed:volume
78
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
34-9
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:12528875-Adult
,
pubmed-meshheading:12528875-Aged
,
pubmed-meshheading:12528875-Antineoplastic Agents
,
pubmed-meshheading:12528875-Disease Progression
,
pubmed-meshheading:12528875-Disease-Free Survival
,
pubmed-meshheading:12528875-Drug Administration Schedule
,
pubmed-meshheading:12528875-Female
,
pubmed-meshheading:12528875-Follow-Up Studies
,
pubmed-meshheading:12528875-Humans
,
pubmed-meshheading:12528875-Male
,
pubmed-meshheading:12528875-Middle Aged
,
pubmed-meshheading:12528875-Multiple Myeloma
,
pubmed-meshheading:12528875-Recurrence
,
pubmed-meshheading:12528875-Survival Analysis
,
pubmed-meshheading:12528875-Thalidomide
,
pubmed-meshheading:12528875-Treatment Outcome
pubmed:year
2003
pubmed:articleTitle
Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma.
pubmed:affiliation
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA.
pubmed:publicationType
Journal Article
,
Research Support, U.S. Gov't, P.H.S.
,
Research Support, Non-U.S. Gov't